WIF 1906
Alternative Names: WIF-1906Latest Information Update: 04 Mar 2021
At a glance
- Originator Whanin Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 16 Feb 2021 WIF 1906 is available for licensing as of 16 Feb 2021. https://www.whanin.com/_commonBase/content.php?co_id=outlicense_kor#
- 16 Feb 2021 Early research in Cancer in South Korea (unspecified route) before February 2021 (Whanin Pharmaceutical pipeline, February 2021)